Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118028 | 0.88 | MAPT (0.42) | ACLYHSD11B1RXFP1MAPTALDH1A1 | |
| SCHEMBL2117319 | 0.86 | ACLY (0.50) | ACLYHSD11B1PTGES2RXFP1MAPT | |
| SCHEMBL2117692 | 0.81 | MAPT (0.41) | MAPTALDH1A1 | |
| SCHEMBL2119785 | 0.78 | ACLY (0.59) | ACLYHSD11B1PTGES2DRD2HTR2A | |
| SCHEMBL2118075 | 0.78 | CYP3A4 (0.43) | MAPT | |
| SCHEMBL2121533 | 0.76 | MEN1 (0.45) | MAPTALDH1A1 | |
| SCHEMBL2120254 | 0.76 | ACLY (0.51) | ACLYHSD11B1PTGES2RXFP1 | |
| SCHEMBL2117688 | 0.76 | ACLY (0.51) | ACLYHSD11B1PTGES2RXFP1DRD2 | |
| SCHEMBL2119833 | 0.74 | MAPT (0.52) | MAPTALDH1A1BRD4 | |
| SCHEMBL2119300 | 0.74 | ACLY (0.54) | ACLYHSD11B1PTGES2MAPTBRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2382190-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS | European Molecular Biology Laboratory (EMBL) (DE) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | ACLY 1578/4885HSD11B1 3376/4885PTGES2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.